{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-23-000016","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.568639+00:00","generated_at":"2026-06-15T04:30:44.453314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics Q1 net loss $12.0M; COO retiring; WTX-124 data expected 4Q23","bullets":["Net loss of $12.0M improved from $15.3M in Q1 2022; cash and equivalents $147.9M.","Collaboration revenue of $4.5M from Jazz Pharma licensing agreement; R&D spend $11.7M.","COO Reid Leonard retiring effective June 30, 2023; founding executive team member.","Phase 1/1b WTX-124 monotherapy data (safety, tolerability, efficacy) expected 4Q 2023.","New candidate WTX-712 (IL-21 INDUKINE) preclinical data presented at AACR 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-23-000016","json":"https://secwatch.observer/filing/0001785530-23-000016.json","markdown":"https://secwatch.observer/filing/0001785530-23-000016.md","text":"https://secwatch.observer/filing/0001785530-23-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/0001785530-23-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/howl-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:30:44.453314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b016f39c760f5644d28e23ea601832a0759935b7","claim":"Werewolf Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue Collaboration revenue was $4.5 million.","evidence_excerpt":"sufficient to fund its operational expenses and capital expenditure requirements through at least the fourth quarter of 2024. • Collaboration revenue: Collaboration revenue was $4.5 million for the first quarter of 2023, compared to zero for the same period in 2022. Collaboration revenue is related to partial recognition of the $15.0 million upfront payment received","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/0001785530-23-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"Collaboration revenue was $4.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}